7 posts in this category
The FDA warned Novo Nordisk for not reporting deaths and serious side effects tied to its GLP-1 medications. Here is what happened.
India’s GLP-1 patent expiry may lower prices there first. Learn what it could mean for US access and affordability.
Hearing new GLP-1 names? Learn why language changed, what stayed the same, and how to tell if your medication actually changed.
Learn how to identify fake Ozempic, check packaging and lot numbers, and avoid online GLP-1 scams. Simple safety tips for families.
Latest updates on Indiana, Florida, and federal GLP-1 compounding laws and what the changes could mean for patient access in 2026.
We’re working hard to keep things updated but give us some grace to work with providers who are potentially changing their offerings around tirzepatide.
We’ve all been hearing about the shortage of tirzepatide or semaglutide, but what is a shortage? How does it impact compounding?
